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Conservation of structure and mechanism
by Trm5 enzymes
THOMAS CHRISTIAN, HOWARD GAMPER, and YA-MING HOU1
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
ABSTRACT
Enzymes of the Trm5 family catalyze methyl transfer from S-adenosyl methionine (AdoMet) to the N1 of G37 to synthesize m1G37-
tRNA as a critical determinant to prevent ribosome frameshift errors. Trm5 is specific to eukaryotes and archaea, and it is
unrelated in evolution from the bacterial counterpart TrmD, which is a leading anti-bacterial target. The successful targeting
of TrmD requires detailed information on Trm5 to avoid cross-species inhibition. However, most information on Trm5 is
derived from studies of the archaeal enzyme Methanococcus jannaschii (MjTrm5), whereas little information is available for
eukaryotic enzymes. Here we use human Trm5 (Homo sapiens; HsTrm5) as an example of eukaryotic enzymes and
demonstrate that it has retained key features of catalytic properties of the archaeal MjTrm5, including the involvement of a
general base to mediate one proton transfer. We also address the protease sensitivity of the human enzyme upon expression in
bacteria. Using the tRNA-bound crystal structure of the archaeal enzyme as a model, we have identified a single substitution
in the human enzyme that improves resistance to proteolysis. These results establish conservation in both the catalytic
mechanism and overall structure of Trm5 between evolutionarily distant eukaryotic and archaeal species and validate the
crystal structure of the archaeal enzyme as a useful model for studies of the human enzyme.
Keywords: burst kinetics; S-adenosyl methionine; m1G37-tRNA; pH-activity profile; structure-guided mutagenesis
INTRODUCTION
The extensive base and backbone modifications present in
natural tRNAs serve to promote translational fidelity and ef-
ficiency (Bjork et al. 1999; Motorin and Helm 2010; Yi and
Pan 2011). Of the more than 100 modifications identified to
date, them1G37 basemodification is strictly conserved in evo-
lution for tRNAs specific for leucine (CUN codons, N being
one of the four natural nucleotides), proline (CCN codons),
and one of the arginine isoacceptors (the CGG codon)
(Bjork et al. 2001). This modification is also present in mito-
chondria and chloroplasts and even in Mycoplasma spp., the
latter of which has one of the smallest sequenced genomes
known to date. The m1G37 modification replaces the imino
proton of N1 of guanosine with amethyl group, thus prevent-
ing base-pairing on the 3′ side of the anticodon in +1 frame-
shifts (Fig. 1A,B). Indeed, m1G37 is essential for cell viability;
its elimination leads to accumulation of frameshifts and de-
layed entry of charged tRNA to the ribosome (Bjork et al.
1989; Hagervall et al. 1993; Li and Bjork 1995). In yeast, elim-
ination of m1G37 also promotes misacylation of tRNAAsp
with arginine (Putz et al. 1994). For eukaryotic tRNAPhe spe-
cifically, m1G37 is the substrate for conversion to the hyper-
modified wybutosine via four successive reactions (Noma
et al. 2006). In archaea, m1G37 is important for synthesis of
cysteinyl-tRNACys required as a substrate for decoding cyste-
ine codons (Hauenstein et al. 2008; Zhang et al. 2008).
While m1G37 is conserved in tRNAs, the enzymes that
catalyze its synthesis are unrelated in evolution. Eukaryotes
and archaea employ the Trm5 enzyme (Bjork et al. 2001;
Christian et al. 2004), whereas bacteria use the TrmD en-
zyme (Bystrom and Bjork 1982a,b). While both enzymes
use AdoMet as the methyl donor to convert G37-tRNA to
m1G37-tRNA, they are fundamentally distinct in structure
(Ahn et al. 2003; Christian et al. 2004; Goto-Ito et al. 2008,
2009), in kinetics (Christian et al. 2010b), and in substrate rec-
ognition (Christian and Hou 2007; Lahoud et al. 2011;
Sakaguchi et al. 2012). The lack of similarity between TrmD
and Trm5 has led to the suggestion that specific targeting of
TrmD, without affecting the Homo sapiens Trm5 (HsTrm5),
would be a highly attractive strategy in developing the next
generation of antibiotics (White and Kell 2004).
The potential of TrmD as a leading anti-microbial target
emphasizes the need to better understand HsTrm5 for two
reasons. First, when an inhibitor is identified for TrmD, it
must be critically evaluated against HsTrm5 to eliminate
cross-inhibition in order to ensure species-specific targeting.
However, key aspects of the evaluation remain completely
void for HsTrm5, including kinetic parameters of methyl
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transfer necessary for analysis of cross-inhibition and a struc-
tural model of the enzyme for modeling and identification of
potential cross-reacting chemical groups of inhibitors. This
lack of information is hindering the development of inhibitors
into drugs. Second, given the importance of Trm5 in main-
taining tRNA translational fidelity, it is essential that funda-
mental knowledge of the enzyme in human cells be made
readily available. However, in the only report on HsTrm5
(Brule et al. 2004), the enzyme was studied using nonhuman
tRNA substrates. In general, eukaryotic Trm5 enzymes are
poorly understood. The only other eukaryotic Trm5 that has
been studied is the enzyme of Saccharomyces cerevisiae (Lee
et al. 2007), which was reported to recognize mitochondrial
initiator tRNAMet.
The major question in the study of HsTrm5, and more
broadly eukaryotic enzymes, is the relationship with their
archaeal counterparts. While eukaryotic and archaeal Trm5
enzymes are grouped as one family, the correlation bet-
ween the two divisions in sequence, structure, and catalytic
mechanism is not known. At present, the archaeal MjTrm5
(Methanococcus jannaschii) is the best-characterized enzyme,
having an extensive set of kinetic data (Christian et al. 2010b)
and well-defined crystal structures, including a binary struc-
turewith sinefungin (an inactive AdoMet analog) and a terna-
ry structure with AdoMet and tRNA (Goto-Ito et al. 2008,
2009). However, whether MjTrm5 is a valid model to study
HsTrm5 or other eukaryotic enzymes remains an open ques-
tion and cannot be predicted based on sequence alone.
Indeed, a sequence alignment by T-coffee (Notredame et al.
2000) revealed only moderate homology between HsTrm5
and MjTrm5, showing 29% identity and 53% similarity, in
contrast to 80% identity and 95% similarity among TrmDs.
Also, there exist species-specific differences between ar-
chaeal and eukaryotic enzymes (Christian et al. 2010a), whose
meaning is unknown. Furthermore, purification yields of
HsTrm5 in bacteria have been noted as low (Brule et al.
2004), in contrast to high yields of MjTrm5 (Christian et al.
2004), indicating at least in part the possibility of protease
sensitivity of the human enzyme relative to the archaeal
enzyme.
Here we address the correlation between HsTrm5 and
MjTrm5 in two parts, with the first using a kinetic approach
to evaluate the conservation of catalytic properties of the
two enzymes and the second using the tRNA-bound structure
of the archaeal enzyme as a model to evaluate the overall sim-
ilarity with the human enzyme. We show that, despite their
modest sequence homology, the two enzymes are fundamen-
tally similar in both the catalyticmechanism and overall struc-
ture, suggesting that the available structures of MjTrm5 can
provide a useful model to studyHsTrm5. This study provides
direct information for HsTrm5 and a framework necessary
and most relevant to human health in the anti-microbial tar-
geting of TrmD.
RESULTS AND DISCUSSION
Protease sensitivity of HsTrm5 in Escherichia coli
HsTrm5 was expressed in Escherichia coli with a C-terminal
His tag, based on the Kazusa sequence (Nagase et al. 2000).
The Kazusa sequence differs from the annotated genomic se-
quence by lacking the N-terminal peptide V2LWILWRP9 of
the genomic sequence, and by containing a K394 residue in-
stead of glutamate (numbering based on theKazusa sequence)
(Supplemental Fig. S1) at a nonconserved position. The lack
of the N-terminal peptide was to facilitate cloning, while the
E394K substitutionwas in the Kazusa sequence and not an ar-
tifact. While the expression level of the recombinantHsTrm5
was high upon induction (MW: ∼60 kDa), only a small frac-
tionwas soluble, and the purity after elution fromametal resin
was poor (15%–20%) (Supplemental Fig. S2A), consistent
with a previous report (Brule et al. 2004). Further purification
of the affinity-purified enzyme on monoS, while reaching
90% homogeneity, resulted in significant losses of protein
quantity. Because the affinity-purified enzyme was as active
as the monoS-purified enzyme on the transcript of human
tRNACys as a substrate (Fig. 1B; Supplemental Fig. S2B), we
used the affinity-purified enzyme throughout this work.
Among the impurities in the affinity-purified enzyme, a
27-kDa protein was most persistent, which was also observed
upon expression of MjTrm5 in E. coli but to a lesser extent
(Christian and Hou 2007). An LC/MS/MS analysis of the
smaller protein showed that it was a degradation product, rep-
resenting the C-terminal half of the protein. Detailed MS/MS
analysis showed that the cleavage sites occurred at theN termi-
nus to M252, V254, M261, and T263 (Supplemental Fig. S3).
FIGURE 1. Synthesis of m1G37-tRNA. (A) Trm5 catalyzes the conver-
sion of guanosine to 1-methyl-guanosine (m1G37) in tRNA, using
AdoMet as themethyl donor. (B) The sequence and cloverleaf secondary
structure of human tRNACys, which was used as the substrate for
HsTrm5 in this study. The target G37 is circled.
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The persistent appearance of the 27-kDa protein suggested
that the soluble fraction of HsTrm5 when expressed in E.
coli was sensitive to proteolysis, which was one of the reasons
for the poor yield of the enzyme relative toMjTrm5.
Kinetic analysis of HsTrm5
The affinity-purified HsTrm5 was examined for its steady-
state activity on the transcript of human tRNACys, similar to
the previous analysis of MjTrm5 with a transcript of the ar-
chaeal tRNACys (Christian et al. 2004, 2010b; Sakaguchi
et al. 2012). The transcript of human tRNACys had a capacity
of methylation to ∼70% levels in extended time. The methyl-
ation reaction monitored methyl transfer from [3H-methyl]-
AdoMet to G37-tRNA, producing 3H-m1G37-tRNA and
releasing S-adenosyl homocysteine (AdoHcys). Steady-state
activity as a function of AdoMet concentrationwith saturating
tRNA revealed Km (AdoMet) of 0.42 ± 0.08 μM and kcat of
0.023 ± 0.003 sec−1, closely similar to values ofMjTrm5 [Km
(AdoMet) of 1.0 ± 0.1 μM and kcat of 0.017 ± 0.002 sec
−1]
(Table 1; Christian et al. 2006). Separately, steady-state ac-
tivity as a function of tRNA in the presence of saturating
AdoMet revealed Km (tRNA) of 0.47 ± 0.04 μM and kcat/Km
(tRNA) of 0.05 ± 0.01 μM−1 sec−1, also closely similar to val-
ues for MjTrm5 [Km (tRNA) of 0.70 ± 0.05 μM and kcat/Km
(tRNA) of 0.024 ± 0.003 μM−1 sec−1) (Table 1; Christian
et al. 2006).
Pre-steady-state assays were also performed, with the en-
zyme in molar excess of AdoMet and with tRNA saturating
to permit only one methyl transfer on the enzyme. The rate
constant of each time course represented a composite term
for all reaction steps from enzyme-substrates binding and up
to and including the formation of m1G37-tRNA (Johnson
1998). All time courses were well fit to a single exponential
equation (Supplemental Fig. S4A), indicating rapid equi-
librium binding. Control experiments
confirmed that the mixing order did
not affect the rate of methyl transfer.
Fitting the data of kobs as a function of
enzyme concentration to a hyperbola
(Supplemental Fig. S4B) revealed the dis-
sociation constant Kd (AdoMet) (1.1 ±
0.1μM),which is closely similar to the val-
ue of MjTrm5 (Christian et al. 2010b).
Similarly, fitting the data of kobs as a func-
tion of enzyme concentration in excess
of tRNA and with saturating AdoMet
revealed Kd (tRNA) of 1.8 ± 0.1 μM
(Supplemental Fig. S4C,D), also closely
similar to the Kd (tRNA) of 1.4 ± 0.1 μM
of MjTrm5 (Table 2; Christian et al.
2010b). The maximum rate constant
kchem (0.09 ± 0.01 sec
−1), which included
both the pre-chemistry isomerization of
the enzyme and the chemistry of methyl
transfer, was again similar to that ofMjTrm5 (Table 2).
The Kd values of pre-steady-state assays were interpreted
as the equilibrium dissociation constant, due to the rapid
equilibrium binding conditions (Johnson 1998). This inter-
pretation has been confirmed forMjTrm5, using the intrinsic
enzyme tryptophan fluorescence as a probe for equilibrium
binding of tRNA in the presence of saturating sinefungin
(Sakaguchi et al. 2012). The addition of tRNA to the enzyme
resulted in quenching of the intrinsic fluorescence and the
measurement of the quench as a function of tRNA revealed
a Kd (tRNA) of 1.3 ± 0.6 μM, closely similar to the kinetic
Kd (tRNA) determined for MjTrm5 (1.4 ± 0.1 μM) and for
HsTrm5 (1.8 ± 0.1 μM). Based on the kinetic Kd of each en-
zyme as the equilibrium binding constant, the catalytic effi-
ciency of methyl kchem/Kd (tRNA) was closely similar for the
two enzymes (0.05 ± 0.01 μM−1 sec−1 for HsTrm5 and 0.09
± 0.01 μM−1 sec−1 for MjTrm5).
The rate-determining step
MjTrm5 previously showed a rapid burst of product synthesis
in a pre-steady-state assay, followed by a slower and linear syn-
thesis over time (Christian et al. 2010b). The burst suggested
that product synthesis in the first turnover was fast, but that
product release from the enzyme was slow, thus limiting the
rate of subsequent turnovers. In contrast, TrmD showed a
linear synthesis of product over time, suggesting that the slow
step occurred before or during methyl transfer (Christian
et al. 2010b). Similar toMjTrm5,HsTrm5 also showed a rapid
burst of product synthesis followed by a steady-state rate
(Fig. 2). Fitting the burst data yields kchem of 0.13 ± 0.02
sec−1 and kcat of 0.020 ± 0.002 sec
−1, similar to values deter-
mined by separate steady-state and pre-steady-state analysis
(Table 1). Extrapolation of the burst plot to the ordinate yield-
ed an estimate for the active enzyme fraction at 15%–20%,
TABLE 1. Steady-state parameters of HsTrm5 relative to MjTrm5
Km (AdoMet)
(μM)
Km (tRNA)
(μM)
kcat
(sec−1)
kcat/Km (tRNA)
(μM−1 sec−1)
HsTrm5 0.42 ± 0.05 0.47 ± 0.04 0.023 ± 0.003 0.05 ± 0.01
MjTrm5 1.00 ± 0.06 0.70 ± 0.03 0.017 ± 0.002 0.02 ± 0.01
Values for HsTrm5 were obtained from the average of at least three independent experi-
ments. Values for MjTrm5 were taken from the published work (Christian and Hou 2007).
TABLE 2. Pre-steady-state parameters ofHsTrm5 relative toMjTrm5
Kd (AdoMet) (μM) Kd (tRNA) (μM) kchem (sec
−1) kchem/Kd (tRNA) (μM
−1 sec−1)
HsTrm5 1.1 ± 0.1 1.8 ± 0.1 0.09 ± 0.01 0.05 ± 0.01
MjTrm5 0.8 ± 0.1 1.4 ± 0.1 0.12 ± 0.01 0.09 ± 0.01
Values for HsTrm5 were obtained from the average of three independent experiments.
Values for MjTrm5 were taken from the published work (Christian et al. 2010b).
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which corresponds closely to the purity of the affinity-isolated
enzyme. This active-site fraction was used to correct the en-
zyme concentration as was done for MjTrm5 (Christian
et al. 2010b).
The pH-activity profile
The high pKa (∼9.5) of the N1 imino proton of G37 suggested
that enzyme-catalyzed deprotonation would be necessary for
methyl transfer. Indeed the pH-activity profile of MjTrm5
showed that catalysis was dependent on one proton transfer
(Christian et al. 2010a), most likely the transfer of the N1 pro-
ton of G37 to a general base on the enzyme. A pH-activity
profile of HsTrm5 also revealed a steep increase of kobs as the
proton concentration was lowered, up to an asymptote at pH
8.0 (Fig. 3A). We measured kobs at each pH, rather than Kd
and kchem, due to the inability to produce large quantities of
HsTrm5. The logarithmic plot of kobs (log[kobs]) versus pH re-
vealeda slopeof0.5 (Fig. 3B),mostconsis-
tent with one proton transfer upon
deprotonation of theN1ofG37. The value
of 0.5 suggests the possibility that the kobs
of the human enzymemight be a function
of both kchem andKd (tRNA) and that only
one of the two (probably kchem) exhibited
a dependence on pH. This is a notable dif-
ference fromMjTrm5, which displayed a
value close to 1.0 (Christian et al. 2010a).
For the human enzyme, fitting the data
of kobs as a function of pH to a one-proton
transfer equation revealed a pKa of 7.1 ±
0.1 (Fig. 3A), higher by 0.6 units than the
pKa of MjTrm5 (6.5 ± 0.2) (Christian
et al. 2010a).
Kinetic isotope effect
While the pH-activity analysis demonstrated the importance
of one-proton transfer for catalysis, the structure ofMjTrm5
did not identify an appropriately positioned general base for
proton abstraction of the N1 of G37. Instead, the general
base for MjTrm5 was proposed to be E185, which is strictly
conserved as glutamate or aspartate but is located >5 Å away
from the N1 of G37 (Christian et al. 2010a). The location of
E185 far away from the N1 of G37 suggested that proton
abstraction had occurred before the active-site structure was
captured in the crystal, most likely during the induced-fit re-
arrangement of the enzyme with G37 of tRNA. In this model,
the kobs represented the induced-fit process rather than the
chemical step of proton abstraction and thus would not be
sensitive to the isotope effect at theN1 of G37. This hypothesis
was confirmed for both MjTrm5 and HsTrm5 by evaluating
the kinetic isotope effect of themethyl transfer reaction,where
the N1 proton of G37 had been readily exchanged to deute-
rium in the presence of deuterium water (McConnell et al.
1983; Snoussi and Leroy 2001). Pre-steady-state kinetic assays
showed that kobs forMjTrm5 (0.11 sec
−1) and kobs forHsTrm5
(0.012 sec−1) remained unaffected in deuteriumwater relative
to hydrogen water (Fig. 4A,B), indicating that the chemical
step of proton abstraction was not the rate-determining step
for these enzymes. The lack of an effect for both enzymes sup-
ports the notion that they share a common kineticmechanism
involving proton abstraction during a slower and rate-deter-
mining process of induced fit. This induced-fit and proton
abstraction would require the action of the general base and
a conserved arginine side chain to facilitate the rearrange-
ment of electrons (Supplemental Fig. S5).
Evaluation of the active-site structure
The conservation of kinetic features between HsTrm5 and
MjTrm5 suggests the conservation of the active-site structure.
We tested this hypothesis by evaluatingmutations inHsTrm5
(Table 3), based on the ternary structure ofMjTrm5 (Goto-Ito
FIGURE 2. A rapid burst of product synthesis catalyzed by HsTrm5.
Time courses of m1G37-tRNA synthesis under pre-steady-state condi-
tions, showing a rapid burst of product synthesis in the first enzyme
turnover, followed by a slower steady-state rate. Error bars represent
standard errors of three independent experiments. The rate constant
of the first enzyme turnover is shown as kchem, while that of subsequence
enzyme turnovers is shown as kcat.
FIGURE 3. A pH-activity profile ofHsTrm5. (A) A plot of the observed rate constant kobs against
pH. (B) A logarithmic plot of kobs as a function of pH from 6.0 to 9.5. Error bars represent stan-
dard errors of at least three independent experiments.
Conservation of Trm5
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et al. 2009). Due to the limitation in enzyme quantities, we
again performed assays for HsTrm5 variants at a single en-
zyme concentration in excess to tRNA in the presence of sat-
urating AdoMet. To verify the proposed mechanism, we
showed that the E288A mutation of HsTrm5, equivalent to
the E185A mutation ofMjTrm5 at the general base position,
reduced kobs by ∼330-fold, similar to the reduction observed
forMjTrm5 (Christian et al. 2010a). Also, a highly conserved
aspartate residue (D172 in MjTrm5 and D275 in HsTrm5)
in the flexible loop preceding the proposed general base
(Fig. 5A,B) may be involved in the induced-fit movement of
the catalytic process. We showed that the D275A mutation
in HsTrm5 decreased kobs by 33-fold in a magnitude similar
to the 24-fold decrease by the D172Amutation of the archaeal
enzyme, supporting the notion that both enzymes engage this
aspartate likely in the movement of the general base to the
proximity of the N1 of G37.
Within the conserved active-site structure of MjTrm5 and
HsTrm5, we tested archaea- and eukaryote-specific residues.
Of interestwas the residue immediatelyC-terminal to the pro-
posed general base, where the R186Amutation in the archaeal
enzyme decreased kobs by 12-fold, whereas the corresponding
H289Amutation in the human enzymehadno effect. The lack
of an effect in HsTrm5 was further confirmed by the H289R
mutation, representing a switch from the eukaryote-specific
histidine to the archaea-specific arginine. Thus, while this po-
sition in the archaeal enzyme appears important, stabilizing
AdoMet bindingwith a charged hydrogen bond to the carbox-
ylate of the methyl donor (Fig. 5B), it is not important for
HsTrm5. However, at other positions where archaeal versus
eukaryotic sequences differed, we found that sequence differ-
ences do not lead to a different effect on catalysis. For example,
at a position adjacent to the amino group of AdoMet (Fig.
5A), while H162 in MjTrm5 is largely conserved as histi-
dine (∼75%) or tyrosine (∼25%) among archaeal enzymes
(Christian et al. 2010a), the corresponding K264 of HsTrm5
has a wider diversity (e.g., lysine, serine, glutamate, valine,
and isoleucine). However, we found that theH162Kmutation
in the archaeal enzyme, which introduced the human lysine,
and the reciprocal K264H mutation of the human enzyme,
decreased kobs similarly by 150-fold to 180-fold, supporting
the notion that the active site of the two enzymes is generally
well conserved. Also, we showed that the K394E substitution
in HsTrm5, which reproduced the genomic sequence, had
no effect on kobs, indicating that this substitution is not delete-
rious for catalysis and that the enzymeproduced by theKazusa
sequence is essentially identical to that encoded by the geno-
mic sequence.
Evaluation of the overall structure
The conservation of catalytic features between HsTrm5 and
MjTrm5, however, does not mean the conservation of their
overall structure. To probe the similarity of their overall struc-
ture, we addressed the challenge of the protease sensitivity
FIGURE 5. A structure-guided mutational analysis of HsTrm5. (A) An
overall viewof theactive site in thecrystal structureofMjTrm5incomplex
with tRNA and AdoMet (PDB 2ZZN). All of the residues that have been
tested inMjTrm5 and the corresponding residues inHsTrm5 (shown in
parentheses) are highlighted. The G37 in the tRNA is flipped out from
stacking with the anticodon nucleotides, and its N1 is directly opposite
from the methyl group of the bound AdoMet by 2.8 Å. (B) A close-up
view of the stereochemistry of the active site inMjTrm5, showing the en-
zyme stabilization of the O6-carbonyl of G37 by R145 (HsR248) and sta-
bilization of the carboxyl group of AdoMet by R186 (HsH289), allowing
the placement of the methyl group directly opposite from the N1-proton
of G37 by 2.8 Å. The catalytically important E185 (HsE288), which likely
acts as a general base, and the highly conserved D172 (HsD275), which
may participate in the movement of the general base, are both shown.
FIGURE 4. Analysis of kinetic isotope effect. (A) Kinetics of m1G37-
tRNA synthesis catalyzed by MjTrm5, showing a virtually identical
kobs of 0.11 sec
−1 in H2O and in D2O, with standard errors of 0.02.
(B) Kinetics of m1G37-tRNA synthesis catalyzed by HsTrm5, showing
a virtually identical kobs of 0.012 sec
−1 with standard errors of 0.001.
Data for H2O are shown in closed triangles; data for D2O are shown
in closed circles.
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of the human enzyme relative to the archaeal enzyme. If
the two enzymes share a similar structure, then a structure-
guided site-specific substitution in the human enzyme to
model the archaeal enzyme should confer an archaeal-like
stability to the human enzyme. Because the protease-sensi-
tive sites of the human enzymes M252, V254, M261, and
T263 (Supplemental Fig. S3) are nonconserved and outside
of the active site, this made the modeling more challenging.
Modeling of these residues to the tRNA-bound structure of
MjTrm5 showed that, while M252 and V254 are localized in
a loop that stabilizes G37, M261 and T263 are in a helix
more distant from G37 (Fig. 5A). We found that, indeed, the
single M261L substitution that recapitulated the archaeal res-
idue minimized the 27-kDa protease product upon enzyme
expression inE. coli, indicating improved stability. In contrast,
the T263I substitution had no effect, whereas the double sub-
stitutions (M261L and T261I) had the same effect as the single
M261L substitution (Supplemental Fig. S6). Importantly, the
single M261L substitution retained the full enzyme activity
(Table 3), indicating that the substitution is not involved in
catalysis but in structural stability, at least for expression in
E. coli. The successful remodeling of the human enzyme for
expression in E. coli, based on modeling with the archaeal
structure, demonstrates the overall structural similarity of
the two enzymes and provides validation that the archaeal
structure is a reasonable working model for studies of the hu-
man enzyme.
CONCLUSION
The interest in Trm5 structure and mechanism has been high
because of its fundamental distinction from the bacterial
TrmD, which is a leading target in developing the next gener-
ation of antibiotics (White and Kell 2004). However, the in-
formation on HsTrm5, in particular, has been limited, thus
hampering the progress of drug development against TrmD.
For HsTrm5, its moderate sequence similarity with MjTrm5
is not sufficient to support structural andmechanistic similar-
ity.We showhere that, despite themoder-
ate sequence similarity, HsTrm5 is
fundamentally similar to MjTrm5 in ca-
talysis (Figs. 2–4; Tables 1, 2), including
the occurrence of one-proton transfer in
an induced-fit process of methyl transfer.
We also show that HsTrm5 is similar to
MjTrm5 not only in the active site (as in-
ferred from kinetic data) but also in
broader regions of the overall structure
that control stability (Table 3). However,
this study also identifies two features
where HsTrm5 differs from MjTrm5. In
one, the value of 0.5-proton transfer of
HsTrm5 versus one-proton transfer of
MjTrm5 (Fig. 3) suggests amore complex
meaning of kobs for the human enzyme. In
theother,while theresidueC-terminal to thegeneralbaseplays
an important role for the archaeal enzyme by stabilizing the
carboxyl endofAdoMet (R186), it is not important for the hu-
man enzyme (H289). Further studies are necessary to illumi-
nate the structural basis of these differences.
An important contribution of this study is the valida-
tion of the MjTrm5 ternary structure as a useful model for
HsTrm5.The successful utilization of the structure to remodel
HsTrm5 for protease resistance, even at nonconserved posi-
tions outside of the active site, is a strong testament for the val-
idation. This validation of the archaeal structure is important,
given the difficulty to obtain large quantities of HsTrm5 for
structural analysis. However, caution should be exercised
during modeling of the archaeal structure. For example, yeast
Trm5 is localized in thenucleus,where it catalyzesm1G37 syn-
thesis after tRNAPhe ismodifiedwithCm32andGm34 (Nm =
2′-O-methylation in nucleotide N) in the cytoplasm and sent
back to the nucleus (Murthi et al. 2010). The Trm5 product
m1G37-tRNA is then re-exported to the cytoplasm for conver-
sion ofm1G37 to yW37 (Ohira and Suzuki 2011). Such a com-
plex tRNA trafficking mechanism does not exist in archaea,
suggesting the possibility that eukaryotic Trm5 may act on
Cm32- and Gm34-modified tRNAPhe in a distinct G37-re-
cognition mechanism relative to MjTrm5. This possibility
must be addressed with specific analysis of tRNAPhe and
with high-resolution structures of HsTrm5 in complex with
tRNAPhe and an analog of AdoMet. Because of the importance
ofHsTrm5, efforts to obtain its structures should be given pri-
ority in order to produce insight into how eukaryotic Trm5 is
diverged from its archaeal counterpart and how it is separated
from the bacterial TrmD.
MATERIALS AND METHODS
Cloning and expression of HsTrm5
The cDNA sequence forHsTrm5was amplified from the KIAA 1393
plasmid of Kazusa DNAResearch Institute (Kisarazu, Chiba, Japan).
TABLE 3. Pre-steady-state parameters with respect to tRNA for wild-type (WT) and mutants
of HsTrm5
Relative to WT kobs kobs (sec
−1) Relative to WT kobs
WT MjTrm5 1.0 WT HsTrm5 0.09 ± 0.01 1.0
L159 Not determined M261L 0.10 ± 0.01 1/0.9
H162K 1/150 K264H 0.0006 ± 0.0001 1/180
D172A 1/24 D275A 0.0027 ± 0.0003 1/33
E185A <1/300 E288A 0.00027 ± 0.00005 1/330
R186A 1/12 H289A 0.13 ± 0.02 1/0.69
R186H Not determined H289R 0.093 ± 0.01 1/0.97
K272E Not determined K394E 0.09 ± 0.01 1/1
Values for HsTrm5 were obtained from the average of three independent experiments.
Values for MjTrm5 mutations E185A and R186A were taken from the published work
(Christian et al. 2010a), while those for mutations H162K and D172A were determined
from the average of three independent experiments and normalized to the WT value of
0.12 ± 0.04 sec−1.
Conservation of Trm5
www.rnajournal.org 1197
This cDNA encodes F3 to T500 (Supplemental Fig. S1) and was
cloned into the NdeI and XhoI restriction sites of pET22b. The pro-
tein sequence as expressed starts with M1 encoded by the NdeI site,
followed by F2SGRF6 to T500, and ends with a His-tag. The coding
sequence differs from the genomic sequence (http://www.uniprot.
org/uniprot/Q32P41) by having K394 instead of E394. The recom-
binant enzyme was expressed in E. coli BL21(DE3)-RIL and purified
by affinity binding to the His-Link resin (Promega [V882A] in a
sonication buffer [20 mM HEPES at pH 7.5, 250 mM NaCl2, 10
mM β-mercaptoethanol, and 0.2 mM PMSF]). Mutations of the en-
zyme were created using the Quik-Change protocol and confirmed
by DNA sequencing analysis. Enzyme mutants were assayed in the
same way as the wild-type enzyme. Transcripts of HstRNACys were
synthesized by T7 RNA polymerase based on a DNA template cre-
ated from two overlapping oligonucleotides (Zhang et al. 2008)
and were purified by a denaturing 12% PAGE/7 M urea gel.
Mass spectrometry analysis
The analysis, performed as a service at the proteomic center of Ohio
StateUniversity, is described in the legend to Supplemental Figure S3.
Kinetic assays
Steady-state kinetic assays ofHsTrm5 were performed at 37°C in the
same buffer as forMjTrm5 (Christian et al. 2004). Assays for tRNA
parameters were performed with 25 μM [3H-methyl]-AdoMet (80
Ci/mmol) (PerkinElmer NET 155H), 0.25–6 μM of HstRNACys
transcript, and 50 nM of the enzyme, while those for AdoMet pa-
rameters were measured with tRNA saturated at 6 μM and 0.25–5
μM of AdoMet. Aliquots were removed at time points and precipi-
tated in 5% TCA (trichloroacetic acid), and counts were measured
and corrected for backgrounds and a quenching efficiency of
∼55%. Parameters were determined from fitting data as a function
of concentration to the Michaelis–Menten equation. Each value was
determined from the average of at least three independent analyses,
showing standard errors, which were obtained by dividing the stan-
dard deviation of each value by the root square of the sample size.
Pre-steady-state kinetics was monitored on an RQF3 KinTek in-
strument (Christian et al. 2010b). One syringe contained enzyme
(0.5–10 μM) with tRNA (0.5 μM) and the other syringe contained
[3H-methyl]-AdoMet (25 μM). Data were fit to the single exponen-
tial equation:
y = yo + A× 1− e−kapp×t
( )
,
where y0 is the y intercept, A is the scaling constant, kapp is the ap-
parent or observed rate constant, and t is the time in seconds to
determine kapp. The analysis of kapp versus enzyme concentration
was fit to the hyperbolic equation:
y = kchem × Eo/(Eo + Kd),
where kchem is the rate constant for the chemistry step, and E0 is
the enzyme concentration. Measurement of Kd (AdoMet) was as
described (Christian et al. 2010b); one syringe contained enzyme
(0.5–10 μM) with [3H-methyl]-AdoMet (0.3 μM), and the other sy-
ringe contained tRNA (6 μM). Datawere fit to the single exponential
equation as above.
Burst analysis was monitored as described (Christian et al.
2010b), upon rapid mixing of HsTrm5 (1 μM) in one syringe with
tRNA (10 μM) and 3H-AdoMet (25 μM) in the second syringe.
The data were fit to the burst equation:
y = yo + A× 1− e−k1×t
( )+ k2 × Eo × t,
where y0 is the y intercept, A is the amplitude of the initial exponen-
tial phase, k1 is the apparent rate constant of the initial exponential
regression, k2 is the apparent rate constant of the steady-state phase,
and t is the time in seconds.
The pH-activity profile
The experiments were performed as described (Christian et al.
2010a). Buffers used for different pH values were as follows: sodium
cacodylate (pH 5.9, 6.1); MES (pH 6.1, 6.3, 6.4, 6.6);MOPS (pH 6.6,
6.8, 7.0, 7.1); glycyl glycine (pH 7.1, 7.3, 7.6, 8.1); and glycine (pH
9.1). If the pH was lower than the normal value, drops of 5 M KOH
were added to the 5× solution such that the 1× solution became
properly adjusted. Reactions at pH lower than 7.3 were monitored
by hand sampling, while those at higher pH values were done on
the RQF3 instrument. No differences in rate were observed for re-
actions run at pH values where two different buffers were used.
HsTrm5 enzyme was used at 3 μM, 37°C, in the reaction buffer
containing a final concentration of 0.1 M buffer, 0.1 M KCl, 6
mM MgCl2, 0.1 mM EDTA, 4 mM DTT, and 0.024 mg/mL BSA.
Upon rapid mixing with 0.5 μM tRNA and 25 μM AdoMet in the
same buffer, the time course of m1G37 synthesis was monitored.
Substrate saturation at pH 6.0, 8.1, and 9.8 was demonstrated by
showing that the kobs remained unchanged upon reducing the en-
zyme and tRNA concentrations by twofold. The consistency in the
measured kobs across all three pH values established that both
tRNA and AdoMet were stable at all relevant pH values. The data
were fit to the equation:
kobs = kA
− + kAH10 pKa−pH
1+ 10 pKa−pH
where kobs is the observed reaction rate at a specific pH, kAH is the
activity of the protonated form of G37 (kAH = 0), kA− is the activity
of the deionized form of G37, and Ka is the equilibrium constant for
the dissociation of the proton.
Kinetic isotope effect
The solvent-exchangeable N1 imino proton of G37 in tRNA was re-
placed with deuterium by incubating the tRNA (previously dried
down) in D2O (Cambridge Isotope Laboratories) for a few minutes
in one syringe of RQF3. The enzyme and AdoMet were incubated in
the water-based buffer in the other syringe. Upon rapid mixing, the
time course of methyl transfer was monitored by taking aliquots and
measuring acid-precipitable counts. The kinetics of MjTrm5 was
measured at the near-saturating 6 μM of the enzyme, while that of
HsTrm5 was measured at 2 μM, due to the difficulty in obtaining
large quantities of the latter. The average value of kobs from two in-
dependent measurements was reported.
Molecular modeling
Figures were drawn with PyMol (PDB 2ZZN), corresponding to the
ternary complex of MjTrm5-tRNACys–AdoMet complex.
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